---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-007003"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:14:16.554996+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anteris reports FY2025 revenue down 29%, net loss widens to $94M; starts PARADIGM trial

## Summary
- FY2025 revenue $1.9M (-29% YoY); net loss $94.1M (23% wider); cash used in ops $77.8M.
- R&D expenses $69.1M focused on DurAVR THV trial preparation; SG&A $26.1M.
- Initiated global PARADIGM pivotal trial for DurAVR THV; FDA IDE approval in Q4 2025.
- Raised $320M in early 2026 including Medtronic investment to fund trial and commercialization.
- Net tangible assets per share turned negative to ($0.01) from $1.74; all IPO proceeds fully used.

## SEC filing metadata
- accession: 0001140361-26-007003
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036126007003/0001140361-26-007003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036126007003/ef20066524_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-007003
- JSON: https://secwatch.observer/filing/0001140361-26-007003.json
- Plain text: https://secwatch.observer/filing/0001140361-26-007003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.